Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2Withdrawn 1Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1Gastrointestinal 1

Conditions

Lymphoma, Extranodal NK-T-Cell 1Liver Neoplasms 1

Interventions

pembrolizumab 437Carboplatin 322Nivolumab 292Cyclophosphamide 281Specimen Handling 271Magnetic Resonance Spectroscopy 257Cisplatin 253Paclitaxel 248Radiotherapy 229Gemcitabine 183Biopsy 182Dexamethasone 181durvalumab 168atezolizumab 151Rituximab 138Doxorubicin 135Lenalidomide 134Bevacizumab 133Docetaxel 131Ipilimumab 129Capecitabine 120Radiation 118Oxaliplatin 114Radiosurgery 113Pemetrexed 112Etoposide 111Fluorouracil 110venetoclax 106fludarabine 106Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × IMC-001 × Clear all
NCT04196465 2026-05-22

NeoChance

Asan Medical Center

Phase 2 Active not recruiting
48 enrolled
Gastrointestinal

Liver Neoplasms

NCT04414163 2026-04-24

A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type

ImmuneOncia Therapeutics Inc.

Phase 2 Active not recruiting
23 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡